|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | China National Medical Products Administration approval summary:anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy显示文摘Background:On May 8,2018,the China National Medical Products Administration(NMPA)approved anlotinib,an orally administered anti-angiogenesis inhibitor,for the treatment of patients with advanced non-small cell lung can-cer(NSCLC)who have progressed after treatment with two or more lines of prior systemic chemotherapy.Main body of the abstract:China NMPA reviewed and inspected a regional double-blinded,placebo-controlled,Phase III trial comparing the overall survival(OS)of NSCLC patients between the anlotinib and placebo arms.A total of 437 patients were randomized(2:1)to receive either anlotinib(n=294)or placebo(n=143)once daily on a 2-week on and 1-week off schedule.Patients with epidermal growth factor receptor(EGFR)or activating anaplastic lymphoma kinase(ALK)genomic tumor aberrations should have disease progression on NMPA-approved therapy.Anlotinib is the first NMPA-approved drug for patients with advanced NSCLC who have progressed on at least two lines of prior systemic chemotherapies in China.The approval was based on a statistically and clinically significant improvement in median OS with anlotinib(9.46 months)compared with placebo[6.37 months;hazard ratio(HR])=0.70,95%confidence interval(CI)=0.55-0.89;two-sided log-rank P=0.002].The confirmed objective response rate(ORR)was 9.2%in the anlotinib arm and 0.7%in the placebo arm.The median duration of response(DoR)was 4.83 months,with a 95%CI of 3.31-6.97 months.The toxicity profile of anlotinib was consistent with that of known anti-angiogenesis inhibitors.Common adverse drug reactions(ADRs)in anlotinib-treated patients included hypertension(67.4%),hand-foot syndrome(43.9%),hemoptysis(14.0%),thyroid stimulating hormone(TSH)elevation(46.6%),and corrected QT interval(QTc)prolongation(26.2%).Short conclusion:Anlotinib demonstrated a clinically significant OS prolongation as a novel therapeutic option for advanced or metastatic NSCLC following at least two lines of chemotherapy. | Ming Zhou Xiaoyuan Chen Hong Zhang Lin Xia Xin Tong Limin Zou Ruimin Hao Jianhong Pan Xiao Zhao Dongmei Chen Yuanyuan Song Yueli Qi Ling Tang Zhifang Liu Rong Gao Yuankai Shi Zhimin Yang | 2019 | Cancer Communications2019，39，1： | 35 |
| 2 | Prognostic value of preoperative prognostic nutritional index and its associations with systemic inflammatory response markers in patients with stage Ⅲ colon cancer显示文摘Background: The prognostic nutritional index(PNI) has been widely applied for predicting survival outcomes of patients with various malignant tumors. Although a low PNI predicts poor prognosis in patients with colorectal cancer after tumor resection, the prognostic value remains unknown in patients with stage Ⅲ colon cancer undergoing curative tumor resection followed by adjuvant chemotherapy. This study aimed to investigate the prognostic value of PNI in patients with stage III colon cancer.Methods: Medical records of 274 consecutive patients with stage Ⅲ colon cancer undergoing curative tumor resection followed by adjuvant chemotherapy with oxaliplatin and capecitabine between December 2007 and December2013 were reviewed. The optimal PNI cutoff value was determined using receiver operating characteristic(ROC) curve analysis. The associations of PNI with systemic inflammatory response markers, including lymphocyte-to-monocyte ratio(LMR), neutrophil-to-lymphocyte ratio(NLR), platelet-to-lymphocyte ratio(PLR), and C-reactive protein(CRP)level, and clinicopathologic characteristics were assessed using the Chi square or Fisher's exact test. Correlation analysis was performed using Spearman's correlation coefficient. Disease-free survival(DFS) and overall survival(OS)stratified by PNI were analyzed using Kaplan-Meier method and log-rank test, and prognostic factors were identified by Cox regression analyses.Results: The preoperative PNI was positively correlated with LMR(r= 0.483, P < 0.001) and negatively correlated with NLR(r =-0.441, P < 0.001), PLR(r =-0.607, P < 0.001), and CRP level(r =-0.333, P < 0.001). A low PNI(≤49.22)was significantly associated with short OS and DFS in patients with stage ⅢC colon cancer but not in patients with stage ⅢA/ⅢB colon cancer.In addition, patients with a low PNI achieved a longer OS and DFS after being treated with6-8 cycles of adjuvant chemotherapy than did those with < 6 cycles. Multivariate analyses revealed that PNI was independently associated with DFS(hazard ratios 2.001; 95% confidence interval 1.157-3.462; P = 0.013).Conclusion: The present study identified preoperative PNI as a valuable predictor for survival outcomes in patients with stage Ⅲ colon cancer receiving curative tumor resection followed by adjuvant chemotherapy. | Jianhong Peng Rongxin Zhang Yixin Zhao Xiaojun Wu Gong Chen Desen Wan Zhenhai Lu Zhizhong Pan | 2017 | Chinese Journal of Cancer2017，36，11： | 11 |
| 3 | Exposure to polycyclic aromatic hydrocarbons and risk for premature ovarian failure and reproductive hormones imbalance显示文摘Polycyclic aromatic hydrocarbons(PAHs)are a typical class of persistent organic pollutants that is ubiquitous worldwide.Previous animal studies suggested that PAHs had adverse effects on female reproduction.However,the human data regarding relationship of PAHs exposure with women reproductive health,such as ovarian dysfunction,are scarce.In this case-control study,the associations of serum levels of PAHs with the risk of premature ovarian failure(POF)and reproductive hormones in Chinese women were investigated,with recruiting 157 POF patients and 217 healthy women.The serum levels of 12 types of PAHs,as well as reproductive hormones,including follicle-stimulating hormone,luteinizing hormone and anti-mullerian hormone,were determined.In the logistic regression models,most individual PAH congeners showed significantly positive correlations with the risk of POF(p<0.05),except for fluorine and pyrene.Benzo(a)pyrene(BaP),as the most carcinogenic PAH congener,was observed to be significantly positively associated with the risk of POF.After adjustment for age,body mass index,educational levels and household income,per one-unit increase in the log-transformed BaP concentration was significantly correlated with 2.191-fold increased risk of POF(OR=2.191,95%CI:1.634-2.938,p<0.05).To the best of our knowledge,this is the first study to report an association between internal exposure levels of PAHs and the increased risk of POF in women. | Xiaoqing Ye Wuye Pan Chunming Li Xiaochen Ma Shanshan Yin Jianhong Zhou Jing Liu | 2020 | Journal of Environmental Sciences2020，32，5： | 10 |
| 4 | Ⅲ期结肠癌患者术前预后营养指数的预后价值及其与全身炎症反应标志物的相关性显示文摘背景与目的预后营养指数(prognostic nutritional index,PNI)已广泛应用于预测各种恶性肿瘤患者的生存结局。虽然低PNI预测肿瘤切除后的结直肠癌患者的预后不良,但对接受根治性肿瘤切除术后辅助化疗的Ⅲ期结肠癌患者的预后价值仍未知。本研究旨在探讨PNI对Ⅲ期结肠癌患者的预后价值。方法本文回顾了2007年12月至2013年12月期间,274例接受根治性肿瘤切除术后接受奥沙利铂和卡培他滨辅助化疗的Ⅲ期结肠癌的连续患者的医疗记录。采用受试者工作特征(receiver operating characteristic,ROC)曲线分析确定最佳PNI临界值。采用卡方检验或Fisher’s精确检验评估PNI与全身炎症反应标志物[包括淋巴细胞与单核细胞比值(lymphocyte-to-monocyte ratio,LMR)、中性粒细胞与淋巴细胞比值(neutrophil-to-lymphocyte ratio,NLR)、血小板与淋巴细胞比值(platelet-to-lymphocyte ratio,PLR)、C反应蛋白(C-reactive protein,CRP)水平]和临床病理特征的相关性。采用Spearman’s相关系数进行相关分析。采用Kaplan-Meier法和log-rank检验分析PNI分层的无病生存期(disease-free survival,DFS)和总生存期(overall survival,OS),并通过Cox回归分析确定预后因子。结果术前PNI与LMR呈正相关(r=0.483,P <0.001),与NLR(r=-0.441,P <0.001)、PLR(r=-0.607,P <0.001)和CRP水平(r=-0.333,P <0.001)呈负相关。在ⅢC期结肠癌患者中,低PNI(≤49.22)与短OS和DFS显著相关,而在ⅢA/ⅢB期结肠癌患者中则不相关。此外,在PNI低的患者中,接受6–8个疗程辅助化疗的患者比接受<6个疗程治疗的患者获得了更长的OS和DFS。多变量分析显示PNI与DFS独立相关(风险比=2.001;95%置信区间:1.157–3.462;P=0.013)。结论术前PNI是接受根治性肿瘤切除术后辅助化疗的Ⅲ期结肠癌患者生存结局的重要预测指标。 | Jianhong Peng Rongxin Zhang Yixin Zhao Xiaojun Wu Gong Chen Desen Wan Zhenhai Lu Zhizhong Pan | 2019 | 癌症2019，38，1： | 10 |
| 5 | Expression of voltage.gated sodium channel Nav1.5 in non.metastatic colon cancer and its associations with estrogen receptor(ER)-βexpression and clinical outcomes显示文摘Background: Voltage-gated sodium channel 1.5(Nav1.5) potentially promotes the migratory and invasive behaviors of colon cancer cells. Hitherto, the prognostic significance of Nav1.5 expression remains undetermined. The present study aimed to explore the associations of Nav1.5 expression with clinical outcomes and estrogen receptor-β(ER-β)expression in non-metastatic colon cancer patients receiving radical resection.Methods: A total of 269 consecutive patients with pathologically confirmed stages Ⅰ-Ⅲ colon cancer who underwent radical resection were selected. Nav1.5 and ER-β expression was detected by using immunohistochemistry(IHC)on tissue microarray constructed from paraffin-embedded specimens. IHC score was determined according to the percentage and intensity of positively stained cells. Statistical analysis was performed with the X-tile method, k coefficient, Chi square test or Fisher's exact test, logistic regression, log-rank test, and Cox proportional hazards models.Results: We found that Nav1.5 was commonly expressed in tumor tissues with higher mean IHC score as compared with matched tumor-adjacent normal tissues(5.1 ± 3.5 vs. 3.5 ± 2.7, P < 0.001).The high expression of Nav1.5 in colon cancer tissues was associated with high preoperative carcinoembryonic antigen level [odds ratio(OR) = 2.980;95% confidential interval(CI)1.163-7.632; P = 0.023] and high ER-β expression(OR = 2.808; 95% CI 1.243-6.343;p = 0.00 3). Log-rank test results showed that high Nav1.5 expression contributed to a low 5-year disease-free survival(DFS) rate in colon cancer patients(77.2% vs. 92.1%, P = 0.048), especially in patients with high ER-β expression tumor(76.2% vs. 91.3%, P = 0.032). Analysis with Cox proportional hazards model demonstrated that high Nav1.5 expression[hazard ratio(HR) = 2.738; 95% CI 1.100-6.819;P = 0.030] and lymph node metastasis(HR = 2.633; 95% CI 1.632-4.248; P < 0.001) were prognostic factors for unfavorable DFS in colon cancer patients.Conclusions: High expression of Nav1.5 was associated with high expression of ER-β and indicated unfavorable oncologic prognosis in patients with non-metastatic colon cancer. | Jianhong Peng Qingjian Ou Xiaojun Wu Rongxin Zhang Qian Zhao Wu Jiang Zhenhai Lu Desen Wan Zhizhong Pan Yujing Fang | 2017 | Chinese Journal of Cancer2017，36，12： | 7 |
| 6 | 中国国家药品监督管理局批准安罗替尼用于经两种系统化疗后疾病进展的晚期非小细胞肺癌的治疗显示文摘背景2018年5月8日,中国国家药品监督管理局(National Medical Products Administration,NMPA)批准了小分子多靶点抗血管抑制剂盐酸安罗替尼,用于既往经过至少两种系统化疗后疾病进展的晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的治疗。概要中国NMPA审查了一项随机双盲、安慰剂对照的III期临床试验,该临床试验的主要终点为总生存期(overall survival,OS)。试验共纳入437例患者随机分组(2∶1)接受安罗替尼(n=294)或安慰剂(n=143)治疗,每日1次,连服2周,停药1周。表皮生长因子受体(epidermal growth factor receptor,EGFR)基因敏感突变或间变性淋巴瘤激酶(activating anaplasticlymphomakinase,ALK)阳性的患者须经过NMPA已批准的药物治疗后出现疾病进展。安罗替尼为中国NMPA批准的用于治疗既往经过两种及以上系统化疗后疾病进展的晚期NSCLC患者的首个药物。安罗替尼组的中位OS(9.46个月)较安慰剂组[6.37个月;风险比(hazard ratio,HR)=0.70,95%置信区间(confidence Interval,CI):0.55–0.89;双侧log-rank P=0.002]显著延长。安罗替尼组的客观缓解率(objective responserate,ORR)为9.2%,安慰剂组为0.7%。安罗替尼组的中位缓解持续时间(durationofresponse,DoR)为4.83个月,95%CI为3.31–6.97个月。安罗替尼的常见不良反应(adverse drug reactions,ADRs)包括高血压(67.4%)、手足综合征(43.9%)、咳血(14.0%)、促甲状腺激素(thyroid stimulating hormone,TSH)升高(46.6%)、心电图QT间期(corrected QT Interval,QTc)延长(26.2%)。结论安罗替尼显著延长了患者的OS,可作为经二线及以上化疗后晚期或转移性非小细胞肺癌的一种新的治疗方案。 | Ming Zhou Xiaoyuan Chen Hong Zhang Lin Xia Xin Tong Limin Zou Ruimin Hao Jianhong Pan Xiao Zhao Dongmei Chen Yuanyuan Song Yueli Qi Ling Tang Zhifang Liu Rong Gao Yuankai Shi Zhimin Yang | 2019 | 癌症2019，38，12： | 7 |
| 7 | Total mesorectal excision with or without preoperative chemoradiotherapy for resectable mid/low rectal cancer: a long-term analysis of a prospective, single-center, randomized trial显示文摘Background:The preliminary results of our phase II randomized trial reported comparable functional sphincter pres-ervation rates and short-term survival outcomes between patients undergoing total mesorectal excision(TME)with or without preoperative concurrent chemoradiotherapy(CCRT).We now report the long-term results after a median follow-up of 71 months.Methods:Between March 23,2008 and August 2,2012,192 patients with T3-T4 or node-positive,resectable,mid/low rectal adenocarcinoma were randomly assigned to receive TME with or without preoperative CCRT.The following endpoints were assessed:cumulative rates of local recurrence and distant metastasis,disease-free survival(DFS),and overall survival(OS).Results:The data of 184 eligible patients were analyzed:94 patients in the TME group and 90 patients in the CCRT+TME group.In the whole cohort,the 5-year DFS and OS rates were 84.8%and 85.1%,respectively.The 5-year DFS rates were 85.2%in the CCRT+TME group and 84.3%in the TME group(P=0.969),and the 5-year OS rates were 83.5%in the CCRT+TME group and 86.5%in the TME group(P=0.719).The 5-year cumulative rates of local recur-rence were 6.3%and 5.0%(P=0.681),and the 5-year cumulative rates of distant metastasis were 15.0%and 15.7%(P=0.881)in the CCRT+TME and TME groups,respectively.No significant improvements in 5-year DFS and OS were observed with CCRT by subgroup analyses.Conclusions:Both treatment strategies yielded similar long-term outcomes.A selective policy towards preoperative CCRT is thus recommended for rectal cancer patients if high-quality TME surgery and enhanced chemotherapy can be performed. | Fulong Wang Wenhua Fan Jianhong Peng Zhenhai Lu Zhizhong Pan Liren Li Yuanhong Gao Hui Li Gong Chen Xiaojun Wu Peirong Ding Zhifan Zeng Desen Wan | 2018 | Cancer Communications2018，38，1： | 6 |
| 8 | Is there a survival benefit from adjuvant chemotherapy for patients with liver oligometastases from colorectal cancer after curative resection?显示文摘Background:Although colorectal oligometastases to the liver can potentially be cured with aggressive local abla-tion,the efficacy of adjuvant chemotherapy(ACT)for such metastasis remains unclear.The present study explored the effects of ACT on patients with colorectal liver oligometastases(CLO)after curative resections and aimed to iden-tify patients who could benefit from ACT.Methods:We retrospectively analyzed 264 eligible patients with CLO who underwent curative resection between September 1999 and June 2015.Recurrence-free survival(RFS)and overall survival(OS)were analyzed using the Kaplan-Meier method and log-rank test;prognostic factors were a by Cox regression modeling.Results:Among 264 patients,200(75.8%)patients received ACT and 64(24.2%)did not receive ACT.These two groups did not significantly differ in clinicopathologic characteristics,and had comparable 3-year OS and RFS rates(RFS:42.1%vs.45.7%,P=0.588;OS:69.7%vs.62.7%,P=0.446)over a median follow-up duration of 35.5 months,irrespective of preoperative chemotherapy.ACT markedly improved 3-year OS in high-risk patients with Memorial Sloan-Kettering Cancer Center clinical risk scores(MSKCC-CRS)of 3-5(68.2%vs.33.8%,P=0.015),but presented no additional benefit in patients with MSKCC-CRS of 0-2(72.2%vs.78.6%,P=0.834).In multivariate analysis,ACT was independently associated with improved OS in patients with MSKCC-CRS of 3-5.Conclusions:ACT might offer a prognostic benefit in high-risk patients with CLOs after curative liver resection,but not in low-risk patients.Therefore,patients’risk status should be determined before ACT administration to optimize postoperative therapeutic strategies. | Zhizhong Pan Jianhong Peng Junzhong Lin Gong Chen Xiaojun Wu Zhenhai Lu Yuxiang Deng Yujie Zhao Qiaoqi Sui Desen Wan | 2018 | Cancer Communications2018，38，1： | 4 |
| 9 | Cholera Caused by a New Clone of Serogroup O1 Vibrio cholerae-Beijing Municipality,China,June 2021显示文摘Several lineages have been identified in the population of serogroup O1 Vibrio cholerae(V.cholerae)(1-3).The strains,which were responsible for the ongoing seventh cholera pandemic,were in Lineage 2.Nearly all the V.cholerae strains in this lineage carried genes coding cholera toxin(ctxAB)(1-2).Lineage 3b consists of strains isolated from different continents and the vast majority of strains in this lineage lack the ctxAB genes. | Hanqiu Yan Bo Pang Xin Lu Zhiyong Gao Pan Lu Xin Zhang Mengyu Wang Lingyu Shen Wenxuan Zhao Jianhong Zhao Weili Liang Lei Jia Haijian Zhou Zhigang Cui Xiaoli Du Biao Kan Quanyi Wang | 2022 | China CDC weekly2022，4，2： | 3 |
| 10 | 对可切除的中/低位直肠癌是/否进行术前放化疗的全直肠系膜切除术研究:一项前瞻性、单中心、随机试验的长期分析显示文摘背景与目的我们的Ⅱ期随机试验的初步研究结果显示,对进行全直肠系膜切除术(total mesorectal excision,TME)的患者是/否进行术前同步放化疗(concurrent chemoradiotherapy,CCRT),二者的功能性括约肌保留率和短期生存结局相近。在经过中位71个月的随访后,现报告这一长期试验的结果。方法在2008年3月23日至2012年8月2日期间,192例患有T3–T4或淋巴结阳性、可切除的中/低直肠腺癌患者被随机分为接受或不接受术前CCRT组,之后均进行TME。评估以下终点:局部复发和远处转移的累积率、无病生存(disease?free survival,DFS)和总生存(overall survival,OS)。结果对入组的184例患者资料进行分析,其中TME组有94例,CCRT+TME组有90例。在整个队列中,5年DFS和OS率分别为84.8%和85.1%。CCRT+TME组的5年DFS率为85.2%,TME组为84.3%(P=0.969);CCRT+TME组的5年OS率为83.5%,TME组为86.5%(P=0.719)。在CCRT+TME和TME组中,局部复发的5年累积率分别为6.3%和5.0%(P=0.681),远处转移的5年累积率分别为15.0%和15.7%(P=0.881)。通过亚组分析,接受CCRT未观察到5年DFS和OS的显著改善。结论两种治疗方案的长期结局相近。因此,如果可以进行高质量的TME手术和强化化疗,建议选择性地对直肠癌患者进行术前CCRT。 | Fulong Wang Wenhua Fan Jianhong Peng Zhenhai Lu Zhizhong Pan Liren Li Yuanhong Gao Hui Li Gong Chen Xiaojun Wu Peirong Ding Zhifan Zeng Desen Wan | 2019 | 癌症2019，38，5： | 2 |
| 11 | Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer:a Chinese single-center experience显示文摘Background:A fixed 8-cycle oxaliplatin and capecitabine(XELOX)regimen has been the standard adjuvant therapy for patients with stage III colon cancer.However,completing the full-cycle of oxaliplatin is often associated with severe neurotoxicity.To spare patients from the toxic effects,without comprising the required efficacy,we evaluated the safety and efficacy of a modified XELOX(mXELOX)adjuvant chemotherapy regimen with 6 cycles of oxaliplatin and a full cycle of capecitabine.Methods:We retrospectively analyzed 330 eligible patients with stage III colon cancer who underwent cura-tive tumor resection followed by mXELOX,standard XELOX or unfinished XELOX adjuvant chemotherapy between December 2007 and April 2015.Associated prognostic factors were investigated and their disease-free survival(DFS)and overall survival(OS)rates were also determined and compared among the different regimen groups.Results:Compared with the standard XELOX group,the mXELOX group had lower total incidence rates of neuro-toxicity(39.3%vs.76.2%,P<0.001),leucopenia(53.6%vs.69.8%,P=0.017)and thrombocytopenia(38.1%vs.56.3%,P=0.011).The standard XELOX and mXELOX adjuvant chemotherapy regimens presented with comparable 3-year DFS rates(86.3%vs.89.2%;P=0.838)and 3-year OS rates(92.7%vs.97.6%;P=0.227).Compared to unfinished XELOX chemotherapy,the oncologic benefits of the mXELOX regimen were greater for patients with T4 tumors(3-year DFS:Hazard ratio[HR],2.184;95%confidence interval[CI],1.051-4.540;P=0.036;3-year OS:HR,4.529;95%CI 1.245-16.479;P=0.022)and for high-risk patients(3-year DFS:HR,1.962;95%CI 0.964-3.993;P=0.044;3-year OS:HR,4.193;95%CI 1.182-14.874;P=0.026).Conclusions:The mXELOX adjuvant chemotherapy presented a comparable survival benefit and lower incidence of toxicity than standard XELOX chemotherapy.It could be an alternative treatment for high-risk patients with operated stage III colon cancer. | Jianhong Peng Weihao Li Rongxin Zhang Junzhong Lin Jinghua Tang Yongshan Wen Zhenhai Lu Xiaojun Wu Zhizhong Pan | 2019 | Cancer Communications2019，39，1： | 2 |
| 12 | A TaqI PCR-RFLP Detecting a Novel SNP in Exon?2 of the Bovine POU1F1 Gene显示文摘 | Chuanying Pan Xianyong Lan Hong Chen Yikun Guo Jianhong Shu Chuzhao Lei Xinzhuang Wang | 2008 | Biochemical Genetics (-)2008，，7： | 1 |
| 13 | Fractional direc- tional derivative and identification of blur parameters of motion -blurred image 显示文摘 | Pan Xiang Ye Yongqiang Wang Jianhong | 2014 | 8 (3) :565 -5762014，8，3： | 1 |
| 14 | Self-etching reconstruction of hierarchically mesoporous F-Ti O2hollow microspherical photocatalyst for concurrent membrane water Purifications显示文摘 | Pan Jiahong Zhang Xiwang Du Alan Jianhong | 2008 | Journal of the American Chemical Society2008，130，11： | 1 |
| 15 | Cross-sectional rainfall observation on the central-western Tibetan Plateau in the warm season:System design and preliminary results显示文摘The central and western Tibetan Plateau(CWTP)is characterized by harsh environment and strong interactions among the spheres of earth as well as significant changes in climate and water cycles over the past four decades.The lack of precipitation observations is a bottleneck for the study of land surface processes in this region.Over the past six years,we have designed and established two observation transects across the south-north and the west-east in this region to obtain hourly rainfall data during the warm season(May-September).The south-north transect extends from Yadong Valley on the southern slope of the Himalayas to Shuanghu County in the hinterland of the plateau,with a total of 31stations;the west-east transect extends from Shiquanhe in the west to Naqu in the central TP,with a total of 22 stations.The observation dataset has been applied to clarify the spatiotemporal characteristics of precipitation in the CWTP,to evaluate the quality of typical gridded precipitation products,to support the development of regional climate models,and to reveal the processes of summertime lake-air interactions.The observation dataset has been released in the National Tibetan Plateau Data Center. | Kun YANG Yingying CHEN Lazhu Changhui ZHAN Xiaoyan LING Xu ZHOU Yaozhi JIANG Xiangnan YAO Hui LU Xiaogang MA Lin OUYANG Weihao PAN Yanghang REN Changkun SHAO Jiaxin TIAN Yan WANG Hua YANG Siyu YUE Ke ZHANG Dingchi ZHAO Long ZHAO Jianhong ZHOU Mijun ZOU | 2023 | Science China Earth Sciences2023，66，5： | 0 |
| 16 | Screening of nanobody against Microcystis from a human phage display nanobody library显示文摘Microcystis species identification is essential for ecological studies and water bloom control.Immunoassays are more specific and convenient and several approaches have been used to develop for diagnosing harmful red tide algae.Howeve r,inve stigations onMicrocystis identification using immunological approaches are still in the initial stage.In this study.Microcystis aeruginosa PCC7806 lysates were utilized as coated antigens to enrich and screen specific Microcystis nanobodies from a human domain antibody display library.After three rounds of enrichment,10 positive monoclonal particles were isolated from the library and the most two positive nanobodies(DAb2 and Dab3)were effectively produced in Escherichia coli BL21.Finally,the DAb2 showed specific immune binding to different Microcystis by the immuno-dot blot assay.This antibody could be used to establish an immunological method to identify Microcystis. | Yao ZU Wenjie MIAO Yu LUO Chen XU Qianhui PAN Siyu CHEN Jianhong LI | 2022 | Journal of Oceanology and Limnology2022，40，5： | 0 |
| 17 | Evaluation of non-verbal cognitive function in infants with severe hearing impairment显示文摘BACKGROUND: The relationship between hearing impairment and verbal developmental deficits in infants has become a hotspot in research, focusing on improving hearing and promoting verbal development. However, language is only one element of cognition. There are other elements of non-verbal cognitive deficits in infants with hearing impairment. OBJECTIVE: This study was designed to compare the differences in gross motor, fine motor, adaptability, and behavioral development between infants with severe hearing impairment and ordinary children of the same age. DESIGN: Case-control observation. SETTING: Department of Otolaryngology-Head Surgery, Bethune International Peace Hospital. PARTICIPANTS: Fifty-two infants with hearing impairment, who received treatment in the Department of Otolaryngology-Head Surgery, Bethune International Peace Hospital from February to December 2007, were confirmed to suffer from severe (or extremely severe) sensorineural deafness by auditory brain-stem response (ABR) and were recruited for this study. The infants comprised 30 males and 22 females. Among them, 18 were aged 0-1 year, 18 were aged 1-2 years, and 16 were aged 2-3 years. An additional 60 individuals, aged 0-3 years, who received developmental monitoring simultaneously, and were confirmed to have normal hearing and verbal ability, were included as controls. Among the control subjects, there were 31 males and 29 females: 20 were < 1 year of age, 22 were between 1-2 years of age, and 18 were between 2-3 years of age. Informed consent for laboratory measurements was obtained from each infant's guardian, and the study was approved by the Hospital Ethics Committee. METHODS: Infant gross motor, fine motor, adaptability, and behavioral development were assessed in the hearing impairment and control infants. Comparison results were expressed as grading standards of development quotient. MAIN OUTCOME MEASURES: Developmental quotient of all subjects was determined using 'psychometric test battery for 0-6 year-old infants', revised by Capital Institute of Pediatrics. Developmental quotient of each factor ≥ 130 points and < 69 points was defined as excellent and mentally disabled, respectively. RESULTS: All determination results were included in the final analysis. There was no significant difference in each factor between hearing-impaired and control infants, who were 1-year-old (P > 0.05). The behavioral developmental quotient was significantly less in hearing-impaired infants compared to control infants, who were between 1 and 2 years of age (P < 0.05). The development quotients of fine motor and behavioral development were significantly less in hearing-impaired infants than in control infants, who were 2-3 years of age (P < 0.05). CONCLUSION: Compared to control infants, severe hearing-impaired infants have a lower behavioral developmental quotient after 1 year and a lower fine motor developmental quotient after 2 years of age. | Shuyu Wang Xiaoming Li Li Zhao Jianhong Li Yuxia Pan | 2008 | Neural Regeneration Research2008，3，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员